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ABSTRACT 
The study aims to develop enzymosomes as an emerging novel drug delivery system for site-specific action. Enzymosomes utilises the 
specific nature of an enzyme, which is binding to a specific substrate at a controlled rate and catalysing product production step. An enzyme 
is encapsulated by coupling covalently to the surface of liposomes/lipid vesicles to form enzymosomes. Enzymes links through acylation, 
direct conjugation, physical adsorption, encapsulation methods to prepare enzymosomes with targeted action. Such novel drug delivery 
systems prove effective drug release and concomitantly reduces undesirable side effects of conventional treatment methods and hence 
showcase improvement in the long-term therapy of the disease. They are a promising substitute to conventional treatment therapies of 
gout, antiplatelet activities etc. Enzymosomes are newly designed supramolecular vesicular delivery systems to be useful as a tool in 
pharmaceutics for the raising of drug targeting and physicochemical properties and hence bioavailability. It shows beneficial effects of 
drugs with a narrow precision because targeting of these drugs to their site of action improves the drugs overall pharmacodynamics and 
pharmacokinetic profile. It also minimizes alterations in the normal enzymatic activity, thus enhancing half-life and achieve enzyme activity 
on targeted sites such as cancerous cells. 
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Novelty in drug delivery is an upcoming targeted system by which 
entities are directed to sites of action specifically [1]. Novel drug 
delivery system (NDDS) emerged its use in various fields like 
pharmaceutical, food and cosmetics industries [2]. It mainly 
accomplishes and overcomes the limitation of conventional drug 
delivery systems i.e. by transferring the entire active moiety of the 
drug to the site of action [3]. It also carries the drug at a rate directed 
manner as required by the body need through proper channels. 
Vesicular carriers act as the latest vehicle of choice for most drugs 
facing problems in bioavailability as well as extents to cells and 
genetic engineering, diagnosis tests, immunology techniques [4-6]. 
Vesicular drug delivery helps in sustaining the drug release at a 
predetermined rate and thus minimizing the dangerous effects of 
drug toxicities, providing importance in treating ocular diseases [7]. 
The structure of such vesicles is user-friendly and used to 
incorporate both hydrophilic and lipophilic drugs [8]. Most carriers 
are having an orderly concentric congregates of lipid bilayer where 
separate sites are utilized for hydrophilic and lipophilic drugs to be 
enclosed, finally turning to amphiphilic nature [9]. The vesicles were 
initially proclaimed by Bingham in 1965 who stated it as Bingham 
bodies. The novel carriers localize their action by spatial induction of 
drug bordering the diseased organ or tissue especially by chemical 
derivatization [10, 11]. Researches on various drugs in glaucoma, 
ulcerative colitis, colon associated diseases, NSAIDS, insulin-like 
drugs are proven to show improved bioavailability and duration of 
action in humans [12]. Vesicular drug delivery decreases the cost of 
treatment and improves pharmacodynamics of it, especially in 
poorly wetting drugs [13]. It could provide great milestones in 
conventional chemotherapy methods where drug penetration and 
the permeability of cells were majorly restrained [14].  
Advantages of novel vesicular drug delivery system  
• It perpetuates the endurance of active drug molecule in the 
systemic circulation. 
• Deferment the elimination reactions of promptly metabolize 
drugs and contributes to controlled release. 
• Incorporates both hydrophilic and lipophilic drugs. 
• Intensifies the stability of medicament. 
• Cost of therapy is minimized by reducing the dose per unit 
formulation 
• Elevate bioavailability especially in water disfavouring drugs. 
• Selective uptake by tissues due to direct drug delivery [15].  
The system utilizes a productive pathway for drug release to the site 
of infection thud reducing adverse effects. The vesicular drug 
delivery system is classified on the basis of composition as lipoidal 
and non-lipoidal carriers. Lipoidal carriers include sphingosomes, 
transferosomes, liposome, emulsomes, and virosome whereas non-
lipoidal carriers include aquasomes, noisome, bilosome etc. Newer 
particulate carriers like lipid particles (using low and high-density 
lipoprotein), nanoparticles, colloidal transfer system, and polymeric 
micelles and various pharmaceutical carriers like cellular 
macromolecule are emerging as useful tools for targeted drug 
delivery [16].  
Cells to vesicles  
“Somes” are a biological cellular structure which makes up the 
internal organs, tissues and contains nucleic acid and genetic 
materials for reproduction and replication. The cell membrane 
incorporating the outer regions of cell in mammalian cells is made of 
phospholipid bilayer [17]. Such a two-layered arrangement of lipid 
structures makes the physiological nature mainly lipophilic.  
Thus lipoidal drugs and proteins can easily cross the membranous 
barriers of the body due to its similar characteristics with cells lined 
by every organ. Such an arrangement of supramolecular lipid 
molecules, similar to a cell membrane is called a vesicle. Vesicles are 
of transport, secretory in nature which are released within our cells 
[18]. Exogenous vesicles can be engulfed by the cells by endocytosis 
and broken down into smaller fragments using lysosomal enzymes. 
The review mainly aims the utilization of such vesicles for targeted 
and site-specific drug delivery of both hydrophilic and lipophilic 
drugs.  
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Enzymes are proteins which folds into different shapes and enable size 
reduced molecules to fit within them. Enzymes are biological catalysts 
acting on a substrate molecule which will be its target site. Enzyme 
converts these reactants to product molecules and thus needed by 
every cell to carry out a reaction at a significant rate. Since enzymes 
are specific and extremely selective, these mainly determine the 
metabolic pathway in which the cell further proceeds [19]. Enzymes 
are site targeted and interlocks with a lock and key mechanism to the 
substrate. The extent of enzyme binding to the substrate determines 
the response of reaction. This specificity of enzymes is exploited by 
combining with the concept of vesicular drug delivery.  
Enzymosome: an overview  
Enzymosomes is an innovative currently emerging targeted 
vesicular drug delivery system. Enzymosomes fundamentally uses 
enzymes, which are having a targeted catalytic function for a 
substrate, which are incorporated within cell-like structures having 
high lipid background. They yield newly designed liposomes, in 
which the enzymes are coupled covalently to the surface of lipid 
molecules. The liposomes so devised to provide proper micro 
surrounding for the enzymes to be incapacitated within them [20]. 
Liposomes are micro-sized vesicles consisting of a lipid bilayer 
enclosing with an aqueous environment. The hydrophilic drugs can 
be solubilised within the internal aqueous compartment and the 
lipophilic drugs are incorporated into the lipid bilayer membrane 
consisting of phospholipid-cholesterol as seen in fig. 1 [21]. The drug 
delivery systems of lipid-based are beneficial in special 
characteristics like lowering volume of distribution, interrupting 
drug clearance and alter the distribution of drug with enhanced 
capillary permeability towards the infected tissues and reducing 
toxicity associated with normal tissues, proving to give an efficient 
nanoscale drug delivering for clinical use [22]. 
  
 
Fig. 1: Diagrammatic representation of structure of lipoid bilayer 
 
Enzymes are having role in catalysis, site-specific pharmacological 
action, prodrug activation, etc. But by reviewing their low lipid 
membrane penetrability, if an enzyme is encased to the surface of 
the liposome, the degradation of the enzyme and transmutations are 
minimized, thus promoting their half-life along with targeted action 
[23]. Enzymosomes is a method of novel vesicular rate directed drug 
conveying system which channels the active form of the drug to the 
site of action and rapidly degrade them for easy uptake. Enzymes 
can be constrained with liposome surface by two approaches; by 
coupling functional hydrophobic compartments like long chain fatty 
acids with the enzyme or by associating the enzyme and the 
phospholipids of the liposome layer [24]. Using the crafted 
approach, enhanced therapeutic efficacy and lower side effects are 
visualized by carrying the therapeutic agent to the destined tissue 
receptors especially seen on an organ or system. Such mutated 
vesicles have enhanced solubility, stability, therapeutic index for the 
sheathed drug molecule. One of the utilization of such lipid 
nanocarriers is in the therapeutics of CNS disorders like epilepsy, 
seizures as these acts as natural attractants of BBB due to its 
lipophilicity [25]. The enzymes acting as therapeutic proteins are 
supplied through polymeric carriers like liposomes, lipoplexes, among 
which the attachment of enzymes to exposed areas of liposomes 
shows maximum response. A vesicular delivery system loaded with 
drugs shows precise results at the site of infection or inflammation, 
with least drug toxicity and side effects, useful for centrally acting 
drugs which have to BBB which plays a fundamental homeostatic role 
of the brain [26]. It also helps to embellish the bioavailability of drugs, 
the merest amount of drug concentration available for systemic 
circulation, by minimizing the purchase cost [27]. The covalently 
bound enzyme and liposome will have minimum alterations in the 
activity of the enzyme and the enzyme-loaded in a vesicle preserves its 
structural integrity and enzymatic activity when tested in vitro and in 
vivo [28]. Advances in the designing of enzymosomes are variably 
applicable in fields like production of new recombinant proteins, 
biotechnological products etc. [29, 30]. 
Advantages of liposomes enzyme conjugates 
• Lowers the exposure to toxic drugs to sensitive tissues. 
• Enhanced stability and encapsulation. 
• Enhanced pharmacokinetic effects (Increase half-life, reduction 
in elimination). 
• Couples specifically with site-specific ligands for active drug 
targeting. 
• Increased efficacy and therapeutic index. 
• Biocompatible. 
• Non-immunogenic for systemic and non-systemic administered 
doses 
• Flexible alteration in electrical properties [31]. 
• Non-toxic. 
• Completely biodegradable. 
• Site restraining effect. 
Disadvantages of liposome-enzyme complex 
• The production cost of liposomes are generally high since these 
come under the class of nanotherapeutics. 
• The constituent phospholipids present in lipid vesicular 
structures may undergo oxidation or hydrolysis. 
• Sometimes shows low solubility and shorter half-life thus 
reduces the bioavailability. 
• The drug molecule which is encapsulated or molecules undergo 
fusion and leakage [32-34]. 
Nair et al. 
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Lipid-based drug carriers 
Lipid-based chemical systems are a monetarily accepted 
methodology for formulating oral, parenteral as well as topical 
dosage forms [35]. The safety and efficacy of such systems prove to 
be its trademark and is attractive for formulations, diagnostics and 
vaccine preparations. It is custom-fit to wide requirements by 
considering the cost, toxicity due to treatments like ultrasound, 
efficacy, and stability including indications of a disease [36]. The 
advantages of such systems are extensive:  
• Have a low-risk portrait 
• Enhanced bioavailability and less plasma concentration 
diversifications 
• Excelling characterization and adaptability of lipophilic excipients 
• Capability to locate key affairs to transfer of technology and 
scale-up production [37] 
Vesicular systems include liposomes based vesicular carriers, lipid 
particulate systems and emulsions. Liposomal carriers accommodate 
modified liposomes, marinosome, phytosome, transferosome [38, 39]. 
Lipid particulate system covers lipid microparticles and lipid 
nanoparticle which are biocompatible in nature and devised in recent 
years. These are advantageous due to regulated drug release, a solid grid 
of stable lipids, physicochemical compatibility and preserve the active 
moiety from degradation. Solid-lipid nanoparticles, lipid drug conjugates 
and other nanostructure lipid carriers are recently developed advanced 
techniques of drug delivery which overtakes the polymer used 
nanoparticles by preventing cytotoxicity [40, 41]. Many research works 
are done on the semisolid type of solid lipid nanoparticles for topical 
drug delivery by incorporating conventional semisolid to dispersion 
mixtures of the systems [42]. Emulsions encircle pickering emulsions, 
nanoemulsions, SLN’s and self-emulsifying delivery systems [43]. 
Enzyme ligation with lipid carrier molecules generate enzymosomes, by 
preserving enzymatic activity and maintaining the structural integrity of 
vesicles, are the key features of enzymosomes. 
Applications of enzymosomes 
Enzymosomes coming underclass of lipid nanoparticulate drug 
delivery system, prepared primarily from phospholipids, which are 
arranged to a bilayer form, incorporates any substance within them, 
independent of solubility, electric charge, molecular weight and thus 
improve GIT absorption and oral bioavailability [44]. The 
enzymosomes can be loaded over lipid-based nanocarriers like 
liposomes, solid-lipid nanoparticles, inorganic nanocarriers like gold 
nanoparticle and magnetic nanoparticles, polymeric nanocarriers 
like nanogels and micelles, protein-mediated nanocarriers like super 
positively charged proteins etc. One assuring a current set of drugs 
without DNA interaction resides within ether and 
alkylphospholipids since cell membrane was used as the target for 
therapeutic intervention. In studies, these were especially effective 
against the clinical treatment of metastases, breast cancer, anti-
inflammatory action etc. [45]. 
Preparation of enzymosomes of surface-exposed superoxide 
dismutase (sod)  
Binding of enzymes directly to the lipids of liposomes is a 
demanding work, yet they are used presently as a persuasive 
mechanism in the treatment of immune-mediated diseases or 
antibody. A model of such direct conjugated therapeutic enzyme 
includes SOD (Super Oxide Dismutase) [46]. The enzyme Cu, Zn-
superoxide dismutase (SOD) was delineated as an innate defence 
mechanism which decreases the teratogenicity produced by toxic 
free radicals. It sets off dismutation of the toxic superoxide radical 
anion O22_ to O2 and H2O2
Through physical adsorption method, spontaneous binding is 
achieved by utilizing the driving electrostatic force as seen in fig. 2 
[51]. Nanoparticles can be congregated from a variety of materials to 
covetable geometries and configurations and thus to acquire useful 
functionalities and properties [52]. Conventional chemotherapy 
treatments bear various adverse reactions along with the inability to 
access the core of the disease. Thus nano-sized polymeric carriers 
prove to be selectively and specifically cell-targeted drug delivery 
[53, [54]. 
 
, disorganising the array of biochemical 
inflammatory processes induced by the free radical. SOD appears to 
be a promising substitute for conventional anti-inflammatory 
therapies, by the use of non-steroidal anti-inflammatory drugs 
avoiding their side effects [47]. The enzyme was not clinically 
acceptable due to its finite characteristics, short half-life time in the 
bloodstream and poor penetration into cells. Many studies was done 
for modifying the substrate on which the enzyme was loaded with 
enhanced half-life and liposomal incorporation efficiency along with 
clinical trials in specific risk groups like obesity, Type 2 DM, etc. [48]. 
To date, the most frequently used application for intracellular SOD 
delivery is targeting protein to cell penetrating peptides (CPPs) or 
protein transduction domains (PTDs). Regardless of the practical 
advantages of the enzyme transduction technology, the main 
interest of this plan is the inefficient escape from the endosome to 
cytosol thus leading to CPP-tagged cargoes secluded in intracellular 
vesicles. Proteins are of importance to biological needs and thus for 
controlling delivery of these peptides, modern techniques of 
encapsulation paved way for its adorable use in the treatment of 
various diseases [49]. 
Construction of nanocarriers 
Techniques like carbon nanotubes, crosslinkednanogel matrices are 
used to prepare polymer colloids which encompass within 
nanocarriers. The productive nature of these systems depends upon 
the biological conditions as well as the intermolecular force of 
attraction. A nanocarrier must be able to carry drugs to the active 
site without deactivation, the drug should be released obeying the 
laws of kinetics, must be able to retain its stability after 
administration and also should actively deliver the drug with site 
specificity [50]. Modifications were done chemically either by 
covalent or non-covalent ligation. Self-assembling of proteins and 
nanocarriers were another alternative.  
 
Fig. 2: Schematic of three loading methods for preparing protein/nanocarrier composites 
Nair et al. 
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The launching of SOD over the liposomal surface is conventional to 
be more beneficial than an encapsulation of enzyme in liposomes, 
since the release of the enzyme from the liposomes at the site of 
inflammation may not be needed to achieve therapeutic activity. To 
accomplish surface localization of SOD on the enzymosomes, the 
method of acylation by covalent linkage of palmitic acid to q-NH2
• By interacting the hydrophobic anchoring molecules like the long 
chain fatty acids to the enzyme. 
 
groups of SOD (Ac-SOD) [55]. The studies speculated that the 
procedure will result in a more hydrophobic enzyme with enhanced 
affinity for the liposomal bilayers. Also by exposing SOD onto the 
external liposomal surface, we also intended to target SOD to 
inflammatory sites. For this liposome were prepared with a long 
circulation time for obtaining localization at the inflammation sites 
and acts as efficient intracellular drug delivery method [56]. 
Through these studies, it was convincingly visualized that long-
circulating liposomes (LCL) tends to localize preferentially at 
inflammation sites after i. v. administration. This preferential 
localization could be due to the inflammatory response provoking a 
locally maximized capillary permeability allowing liposome 
extravasation. Therefore, LCL has attractive prospects for the targeted 
delivery of Ac-SOD. SOD and Ac-SOD was incorporated in two types of 
liposomes: PEG-coated LCL (PEG liposomes) and non-PEG-liposomes 
containing stearyl amine (SA-liposomes). The enzymes are sensitive to 
physical and chemical stress like thermal treatment, thus are 
protected within lipid bilayers maintaining their native conformation 
[57]. Both liposomal formulations were characterized with regard to 
incorporation efficiency, zeta potential, retention of enzymatic activity 
and externally exposed enzyme activity. 
The studies done for preparing and optimizing SOD enzymosomes 
was mainly to enhance longer time of circulation of human blood 
and accumulate the enzyme at the target site, therefore maintaining 
the enzyme flawless within the lipid structure [58]. Hydrophilic 
range therapeutic enzymes are retained or encapsulated within the 
inner aqueous space of prepared vesicles. A liposome, which exhibits 
catalytic action in its intact form, i.e. before it gets destroyed. The 
enzymes could be bound to liposomes by two approaches:- 
• By initially linking enzyme directly to the liposome bilayer 
components of the phospholipids. 
As a result of the first process, the enzyme is assimilated to the 
liposomal membrane, and in the latter step, the docking is between 
liposome bilayer and coupling reaction take place with the liposomal 
surface. Both the processes are having difference in, 
• The stability of the enzyme-liposome complex. 
• A number of enzyme molecules which are entrapped/displayed to 
the outer lipid bilayer. 
• The nature of modified enzymosomes, since there are many 
molecules to which the enzyme could be docked, example 
phospholipids, long chain fatty acids or polymer-like substances 
attached to phospholipids. 
• The method of preparation is generally chosen according to the 
diverse cases of therapeutic needs where enzyme delivery mediated 
by enzymosomes is required.  
A schematic diagram depicted in Gaspar MM et al., where the ligation 
of enzymes to the internal hydrophilic environment, i.e. native 
enzyme occurs and to the lipid bilayer membrane of liposomes by 
the Ac-enzyme [59]. When the liposomes are intact, the enzyme in 
the interiors are not available for reaction. But when the enzymes 
are directly attached to the lipid membrane, the enzyme is available 
for catalytic action even before the liposomal destruction.  
During the unification of hydrophilic enzyme to the acyl residual 
chains of lipids, the process of acylation (addition of acyl functional 
group) occurs resulting in the formation of Ac-enzyme. This result in 
diversion of enzyme from hydrophilic to hydrophobic micro-
environment. The attained hydrophobicity level is inflected by the 
length and number of fatty chains joined to the surface of the 
enzyme. The conservancy of other equities of the modified enzyme 
must be evaluated by using the basic strategies of conjugation. An 
example, L-Asparginase enzyme used for treatment of acute 
lymphoblastic leukaemia, withholds 100% of its catalytic action, if 
the active site of enzyme is hindered with the substrate while 
conjugation. For augmenting a fine dose of Ac-enzyme to the 
liposomal structure and for enabling proper release of enzymes, 
different strategies are used. The partly insertion of Ac-enzyme into 
lipid bilayer or concealed within the hydrophobic lipid vesicular 
matrix. The association Ac-enzyme to the lipid bilayer membrane is 
mainly dependent on several factors, including electrostatic 
interactions between the charges associated with enzymes [60]. The 
efficiency of the Ac-enzyme incorporated to liposome is determined 
by calculating the ratio between catalytic values estimated during 
the intact life period versus the disrupted enzymosomes. The ideal 
characteristics of liposomes play a very useful role during 
construction of enzymosomes which include, the size of the vesicle, 
composition, ionic charge, etc. 
Acylated-sod liposomes 
Generally, the SOD enzymosomes was a homogenous film obtained 
by dispersing aqueous solution containing SOD and thus the non-
bounded enzyme was extruded by ultracentrifugation separation 
method. The prepared enzymosomes were characterized by the 
research work of Gaspar MM et al, by different parameters which 
ensured that the enzymosomes is standard in its characteristics. The 
different parameters included where;  
• Liposome mean particle size (diameter) was analysed using 
dynamic light scattering.  
• Protein coupling to liposomes was assessed after disruption of the 
liposomes with Triton X-100 and sodium dodecyl sulphate (SDS). 
• Free amino acid groups and lipids were determined. 
• Phospholipids by colourimetric assay. 
• The enzymatic activity of Ac-SOD and SOD formulations was 
determined. 
• The enzymatic ability to decrease the speed of autoxidation of 
epinephrine to adrenochrome was assessed. 
• The total activity of enzyme within SOD or Ac-SOD enzymosome 
was determined by initially preparing a series of dilutions to obtain 
a final concentration of protein. 
• The enzymatic activity of the enzyme exposed to the external 
surface was measured. 
• Zeta potential was analysed. 
• The electric field intensity and scattering angle were found. 
• The thermotropic behaviour of the membrane phospholipids of 
enzymosomes was found [61]. 
The results of various works in chemical alterations of SOD were 
presented innovative methodologies for characterizing Ac-SOD and 
analysed if it was superior over plain SOD and other pharmaceutical 
preparations.  
• The surpassing parameters for Ac-SOD evidenced higher affinity 
of it to the hydrophobic area of liposomal bilayer when compared to 
free SOD.  
• The incorporation efficiency of Ac-SOD in SA containing 
enzymosome was set side by side to PEG-liposome, where having 
lower initial (protein/lipoprotein) ratio, because of competition 
between Ac-SOD with cholesterol for inclusion between 
phospholipids. 
• The varied electrostatic interactions suggested that positively 
charged SA-liposome advantageous were as due PEG at the lipid 
surface, it reduced lipid-protein charged interactions. 
Thus Ac-SOD presented substantial activity for the incorporated 
enzyme, which acts independently depending on, rate and extend of 
enzyme release, thus producing a different mechanism of action. 
Thus the undertaken work confirms that the designed enzymosome 
Nair et al. 
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is significant potential since even in the presence of surface PEG 
chains, the PEG-enzymosome converted the substrate. Thus, it was 
not a barrier and the release of the enzyme was not a prerequisite 
for producing dismutation action at the inflamed site. If the Ac-SOD 
enzymosome could be prepared with circular micro-reservoirs, it 
could be markedly ample for expressing its action without 
disruption and also for a sustained release pattern of the enzyme. 
Similar modifications are done for peptides and polymers which 
makes an important drug targeting pathway [62]. Therefore the Ac-
enzymosome could be a replaceable therapeutic agent for an intense 
effect in rheumatoid arthritis and longer flowing active particles for 
reperfusion pathologies. The affinity of SOD for negatively charged 
lipid molecules accounts for at least part of its ability to protect lipid 
membranes from oxygen-induced injury and are valuable tools for 
studying membrane structure and dynamics [63]. 
Designing of immuno-enzymosomes having enhanced enzyme 
targeting capability and cell binding properties 
The potency of traditional anticancer drugs for the treatment of 
chemotherapy is confined due to the inadequacy of discrimination 
between normal as well as cancerous cells. On reviewing the studies 
on immuno-enzymosomes could be used to target enzymes to for 
achieving site peculiar activation of anticancer prodrugs. The 
potency of generating a sole well portrayed liposomal system which 
is having a binding capacity to variety targeted ligands is significant 
worth. These methods offer the hiding of enzyme within small 
packet like structures and releasing them on reaching action site 
[64]. It was stated that enzyme, β-glucuronidase, which was 
proficient in stimulating anthracycline glucuronide prodrugs, when 
coupled with immunoliposomes surface aimed against ovarian 
cancer cells (OVCAR-3). Thus, by cleansing commercially accessible 
enzyme β-glucuronidase (GUS) an immune-enzymosome 
formulation could be prepared which had a 2 times increase in its 
enzyme specific activity when incubated with ovarian cancer cells 
[65]. The principle involves fusion of a cell unique antibody with 
(liposome) immunoliposome enclosing the chemotherapeutic agent, 
thus providing a probability for selective drug transmission and cell-
specific cytotoxicity as seen in fig. 3 [66]. This results in new 
derivatives of therapeutic proteins having minimum immune-
genicity. The antibody-enzyme complex was administered, pursued 
by injection of comparable non-toxic prodrug after binding of the 
complex with cancerous cells and cleared from the blood and 
tissues. Targeted by the enzyme’s action, the prodrug is converted to 
active cytotoxic molecule within the concurrence of tumour cells, 
therefore leading to its selective wiping out. 
Advantages 
• More than one enzyme moiety could be admitted in one targeted 
carrier system. 
• Enhanced enzyme density at the cancer cell surface, thus 
providing efficient conversion of the prodrug. 
• The enzyme GUS was preferred due to its superiority over other 
enzymes, which were present localized intracellular. 
• They cause limited activation of hydrophilic glucoronide drugs 
since they have only low penetration. Thus lowering 
immunogenicity problem. 
The GUS enzyme due to its bulky steric hindrance sometimes could 
negatively affect the coupling with cells. But studies showed that 
even increasing the enzymatic density over the surface provided 
large enzymatic targeting. In studies of Szczupak et al., the electro 
some was used as a tool for the release and action of a cascade of 
enzymes overcoming the drawback of the low number of enzymes 
on the surface [67]. The GUS obtained was initially purified and Fab’ 
fragments were developed. Using these immuno-liposome or the 
enzymosome was generated followed by its characterization. 
  
 
Fig. 3: Specificity of immuno-enzymosomes to target cells 
 
The review of the research work, for the most part, was done to 
cite certain important milestones in the field of nanoscience, 
which can be used as leads for developing efficient drug 
delivering methods for uncompromising diseases. The main 
objectives of the study were to preserve maximum enzyme 
density at cell environment and to quantitatively enhance the 
enzyme without its aggregation by undergoing additional 
conformational changes, which determines the enzymes efficacy 
and selectivity [68].  
As the experiment progresses, the purification of commercially 
available GUS increased two folds its enzymatic action. Thus 
terminating, the density of enzyme up to the level of a steric 
hindrance for interacting with a target antigen could be an effective 
strategy for producing immuno-enzymosomes with maximum 
enzyme targeting capability as seen in fig. 4 [69]. The major 
application of the immuno enzymosomes was in the diagnosis and 
treatment of ovarian carcinomas. Even during the initial stages itself, 
the cancer cells could spread up to the peritoneal cavity.  
The usual surgical removal of tumorous mass followed by 
chemotherapy is done regularly. Thus, for a complete curing with 
the full elimination of residual matters which could otherwise 
further damage the normal cells. The studies thus confirm that by 
giving the immuno-enzymosomes preparation i. p for antibody–
directed enzyme prodrug therapy, the peritoneally injected drug 
could easily gain access to targeted cells to which the enzyme has to 
bind. 
Nair et al. 




Fig. 4: Enzyme bound drug targeting tumour cells 
 
Production alkaline enzymosomes loaded with Bacillus fastidious 
The study done by Tan Q et al. was to judge the promising action of a 
novel alkaline enzymosome for delivering the enzyme, Uricase from 
Bacillus fastidious (UBF) and embellish its biochemical activity, 
therapeutic use and pharmacological characteristics [70]. Uricase have 
a normal physiological action to lower the plasma uric acid level by 
undergoing catalysis of uric acid by oxidation reaction [71]. It was 
proven from studies that it took less time for UBF loaded in the novel 
alkaline enzymosomes (ESUBFs) to diminish the plasma uric acid 
concentration to the normal level from higher, compared to the time 
taken by free UBF [72, 73]. Their results showed that ESUBFs 
effortlessly delivers UBF and positively increasing the total area under 
curve (AUC), half-life (t1/2
The endothelial cells of body consist of an enzyme CD39/NTPDase-1 
which is expressed on the opening side of the cell. It physiologically 
has an ability to rapidly metabolize ATP and ADP, along with AMP 
and minimizing the platelet sensitivity to the major agonists. Thus, 
motivation existed to examine therapeutic anti-platelet 
‘enzymosomes’ formulations that consist of CD39 integrated within 
liposome lipid bilayers. Initially, CD39 enzymatic activity was 
optimized which appears to be dependent on the expression of 
either of its transmembrane domains [81]. The full-length human 
CD39 was generated by using a yeast expression system as a model 
which was purified and reconstituted within a suitable lipid vesicle 
chosen accordingly. The dephosphorylation and formation of ADP 
and ATP were taken as parameters for finding it’s catalytic efficiency 
and was determined both for detergent solubilized CD39 and when 
reconstituted within a lipid membrane. The CD39 containing lipid 
vesicles ability to inhibit platelet activation induced by ADP, collagen 
and thrombin was defined in vitro by platelet aggregometry method. 
A murine model of thromboplastin induced thromboembolism was 
utilized to find out the effectiveness and therapeutic applicability of 
intravenously administered CD39 enzymosomes in limiting platelet 
consumption and death. The reconstitution of human CD39 in lipid 
vesicles caused a reduction of the Km value of nearly an order with 
aconcomitant enhancement in both ADPase and ATPase catalytic 
efficiency [82]. The platelet activation by ADP, collagen, or thrombin 
was effectively inhibited after administration of CD39 lipid vesicles 
thus effectively inhibited platelet aggregation when platelets were 
activated and produced a platelet disaggregation response.  
One drawback obtained from studies was that treatment with CD39 
lipid vesicles enormously limited the reduction in platelet counts 
caused by thromboplastin. The incorporation of the enzyme into a 
lipid bilayer significantly enhanced CD39 enzyme activity when 
compared to its solubilized counterpart. Thus, studies revealed 
treatment with CD39 enzymosomes minimized platelet consumption 
and death rate in the animal model. Thus prepared CD39 enzymo-
somes could be a useful therapeutic option for complementing other 
existing anti-platelet therapies characterized by platelet thrombus 
formation [83]. 
Generation of streptavidin-liposomal conjugates for targeted 
ligand specific applications 
) and catalytic activity as well as modifying 
its biochemical and pharmacological characteristics [74]. Thus ESUBFs 
could be a favourable second choice solution to problems like gout and 
hyperuricemia [75]. It was the additionally accountable advantage of 
the expanded in vivo uricolytic action could be of great clinical 
implication since the clinical dosage given as well as the side effects 
produced during the normal dosage of UBF formulation could be much 
considerably reduced via conjugation [76]. In the work, the 
development of novel alkaline UBF enzymosomes was profitably 
developed to indeed improve the pharmaceutical, biological and 
biochemical properties and exploited for hyperuricemia effects of 
enzyme uricase from Bacillus fastidious. In research work of Szczurek 
et al. the oral delivery of uricase enzyme was found to reduce uric acid 
levels in hyperurecemia rat model [77, 78]. Uricase enzyme had 
constitutional advantages like enhanced selectivity with efficient, fast 
reactivity along with disadvantages like short in vivo half-life with 
limited therapeutic usage. The main aim of encapsulating an enzyme 
within an enzymosomes is to regulate its delivery and also to sustain 
its molecular structure intact.  
The research work included the catalytic activity of the UBF loaded in 
the novel alkaline enzymosomes (ESUBFs) in vitro, which suggested 
almost 3 folds that of free UBF at the optimum pH. Following 
intravenous (i. v.) administration in study model, ESUBFs provided a 
significantly higher area under the plasma concentration (AUC) and 
longer circulation half-life (t1/2) compared with free UBF, similar to 
studies by Xiong H et al. [79]. The preparatory security assessment 
actively exhibited that ESUBFs was acceptable when injected through 
the parenteral route of administration thus used in emergencies of 
enzyme replacement for curing enzyme deficit diseases [80]. The 
systematic investigation trends indicate well the maximized activity of 
encapsulated biochemical and pharmacological characters of alkaline 
enzymosomes. Therefore enzymosomes could be a preferred 
alternative for the formulation of UBF and ESUBFs which might be a 
preferred alternative to therapeutically cure hyperuricemia and gout. 
Antiplatelet activity of CD 39 enzymosomes 
The tetrameric biotin-binding protein, Streptavidin confined from 
Streptomyces avidinii is having a low degree of nonspecific binding in 
immunohistochemistry applications. Thus, it is a quintessential 
choice in various detection systems [84]. It belongs to the avidin 
group of proteins which functions as antibiotics and its specific 
interaction with biotin molecules makes it useful in nonradioactive 
detection systems. Biotin is a vitamin in living cells demanding in 
different biological processes, including cell growth [85]. Formerly, 
when biotin is attached to a molecule, the biotin tag is used to assist 
the progress of affinity purification of molecules using immobilized 
biotin-binding protein. Thus the avidin-biotin interaction is applied 
in Enzyme-linked immunosorbent assay (ELISA), Immuno-
histochemistry (IHC), Cell-surface labelling, Fluorescence-activated 
Nair et al. 
Int J App Pharm, Vol 9, Issue 6, 2017, 1-9 
 
7 
cell sorting (FACS) etc. [86]. Thus, under optimum conditions 
Streptavidin attached to liposome result in well-characterized 
protein-liposome conjugate. The resulting targeted vesicle system 
retains more activity with respect to their size and binds more 
firmly to the biotinylated targeting ligands. The coupling of natural 
circulating cells with enzymes for drug delivery has gained interest 
in later years [87]. 
In the studies, the streptavidin is noncovalently coupled to biotin 
which is a vitamin and phosphatidylethanolamine which is a class of 
phospholipid. The phospholipid was chosen due to its primary role 
in distributing out negative charge produced by anionic membrane 
phospholipids [88]. The researchers used the extrusion method to 
prepare the sample by dissolving the lipid mixture in a solvent 
which was coated over a tube a dried to a thin film by passing a 
stream of appropriate gas under high vacuum [89]. The biotinylation 
process involved the covalent coupling of a protein or a nucleic acid 
with biotin. Biotin combination with streptavidin, a member of 
avidin family is with high affinity and fast action and thus in many 
fields of biotechnology to separate such biotinylated compounds of 
interest. The liposome vesicles were incubated with streptavidin for 
accomplishing its binding and at a constant ratio of streptavidin to 
lipid molecules when maintained, maximum coupling efficiency was 
obtained [90]. This efficient communication between streptavidin 
and biotin containing lipid molecules is utilized in the indirect 
targeting procedures. Other drug discoveries like photoaffinity is 
used as additional mechanisms for molecular interactions and 
targets for the binding site via activation through light [91].  
Another method investigated in studies was the covalent binding 
streptavidin to two lipid derivatives, which contained thiol groups to 
initiate the reaction [92]. In the research work done in the reference 
article, the maleimide derivatives of lipids were cross-connected 
better due to the presence of long spacing reactive arms [93]. The 
enzyme is then coupled with these liposomes and is designed in such a 
manner to use its ability to conjugate in a specific manner with 
membrane-linked antigens, producing different nanocarriers with 
physicochemical features efficient as a drug delivery system [94]. The 
biotinated antibody was coupled with enzyme-linked with liposomes 
which had wide in vivo and in vitro applications. Such applications are 
useful in retention of hydrophilic drugs and fluorescent groups in 
water-loving compartments of targeted liposomes for cell surface 
activity [95]. The conjugates of small size preparations proves longer 
half-life and thus retains their capacity and action more within the 
plasma,varying the infection and acute reaction severity [96].  
CONCLUSION 
Enzymosomes are suitably engineered lipid constructions in which 
there is a suitable mini-environment for the enzyme to be 
immobilized within lipid structures or covalently coupled to the 
outer side of lipids. It has its major application in easiness in 
permeation as well as for targeted drug arrival at tumorous cellular 
sites [97]. These vesicular systems have wide flexibility for drug 
development to overcome several side effects and bioavailability 
problems. The approach of nanosystems of delivering drugs to the 
CNS by permeating through BBB is promising lead for enhancing 
treatment methods like in different type of malignancies [98]. 
Various prodrugs, as well as charged proteins along with complexes, 
are delivered to the brain by the method thus increasing the 
concentration of drug linearly. Even though different carrier nucleus 
has disadvantages like oxidative stress damage, in spite of all they 
have a major role in selecting and targeting and brings a newer 
origin to conventional drug therapies [99]. Various methods like 
biotinylation, pegylation are the latest innovative trends for targeted 
drug delivery. There are various lipoidal and nonlipoidal vesicular 
carrier nanoparticles utilized for sustained drug release and cellular 
targeting. Enzymosomes as one of the lipid bio carrier along with 
others like ethosome, transferosome, pharmacosome, virosome, and 
non-lipoidal ones like niosomes, aquasomesetc. [100]. Each carrier is 
now proven to be successful in their action though various studies. 
From studies of CA Valeetal., it was proven that PEG-SOD 
enzymosomes were having an adequate action to be used 
therapeutically. Liposomes are now becoming clinically accepted 
since they maintain the level of toxicity to a minimum and attains 
enhanced efficacy when compared with free supplements. Review of 
Nair et al., shows that emulsomes are proven carriers for loading 
low water-soluble drugs and thus variable bioavailability when 
compared free drug. Thus enzymosomes can be also an assuring 
carrier nucleus to achieve a newer generation of flexible drug 
designing system in future. 
To advance the better applications of carrier-mediated protein 
delivery the different strategically approved methods. The 
therapeutic enzymes are integrated to carriers of the polymeric 
nature of the hydrophilic area of lipid vesicles and the 
hydrophobized forms assimilated to lipid bilayers of vesicles. Not 
one thing above specified can retain the activity of therapeutic 
protein fully. Other than therapeutic enzymes another method of 
plan is that, its coupling to the outer surface of liposomes, by which 
scientific know-how was developed for an antibody with drug 
preparation. Complexation of the enzyme with lipid nature carriers 
brought about enzymosomes. The seductive characteristics of 
enzymosomes is its enzymatic activity preservation and restraining 
structural integrity. The conception of consolidating the drug to lipid 
vesicles for a more exceptional targeting of the drug at the apt tissue 
terminal is widely accepted. It is discernible that different 
deformable and lipid, rigid supramolecular vesicular constructs have 
tremendous potential to deliver drugs for targeted delivery of 
different bioactive. During last years, repeated researches have been 
going on to achieve the target with the goal of enhanced targeting 
and limiting the dosing frequency. To acquire these efforts, these can 
be formulated in a semi-liquid or liquid drug delivery systems with 
corresponding matching lipid composition. The novel vesicular 
systems actively revealed their therapeutic potential to genetic 
levels from topical one. Using the notions of supramolecular 
chemistry, an enzymosome, a novel vesicular system is capable of 
acquiring the mentioned traits. 
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